Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis.
about
Stem cell transplantation for primary immunodeficiency diseases: the North American experienceB-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?Gene therapy on the moveGenetics of SCIDImproving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiencyB-cell function in severe combined immunodeficiency after stem cell or gene therapy: a reviewTransplantation immunology: solid organ and bone marrow.Transplantation outcomes for severe combined immunodeficiency, 2000-2009.Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: a review of case-based examples of selected immunodeficiencies.Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCIDA multiplex immunoassay using the Guthrie specimen to detect T-cell deficiencies including severe combined immunodeficiency diseaseOutcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioningPositive Family History, Infection, Low Absolute Lymphocyte Count (ALC), and Absent Thymic Shadow: Diagnostic Clues for All Molecular Forms of Severe Combined Immunodeficiency (SCID).IL-21 is the primary common γ chain-binding cytokine required for human B-cell differentiation in vivo.Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism.Radiation-sensitive severe combined immunodeficiency: The arguments for and against conditioning before hematopoietic cell transplantation--what to do?Combined immunodeficiency in the United States and Kuwait: Comparison of patients' characteristics and molecular diagnosis.Long-term outcome of non-ablative booster BMT in patients with SCIDNewborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 yearsScreening for severe combined immunodeficiency in neonates.The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901.Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes.Evidence of innate lymphoid cell redundancy in humans.Primary Immune Deficiency Treatment Consortium (PIDTC) report.Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience.Should newborns be screened for immunodeficiency?: lessons learned from infants with recurrent otitis media.Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects.Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics.Severe combined immunodeficiency: recent developments and guidance on clinical management.T Cell-Depleted and T Cell-Replete HLA-Haploidentical Stem Cell Transplantation for Non-malignant Disorders.Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant ConsoRecommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant ConsortiumLentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.Haematopoietic stem cell transplantation for severe combined immunodeficiency: Long-term health outcomes and patient perspectives.Longitudinal Evaluation of Immune Reconstitution and B-cell Function After Hematopoietic Cell Transplantation for Primary Immunodeficiency.Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey.First Year of Israeli Newborn Screening for Severe Combined Immunodeficiency-Clinical Achievements and Insights.Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.Long term outcomes of severe combined immunodeficiency: therapy implications.
P2860
Q26827162-8216A9CB-4F35-4BE6-8CC6-B5A61DFEDF2EQ26828763-683A85D9-4EAE-44F9-84AF-94A2E5D1731BQ27007012-D459A1A7-1C45-4C99-A23F-E3F454F473FEQ27499229-1AE11F70-F8A3-4888-8F73-ADF587350E66Q33700953-97D60824-A983-4D79-AE16-28C2A9EFAFA4Q33722772-57A8CF67-5196-4699-8B93-BF14085416D0Q33803725-A3219B89-B2FF-4FDB-B002-26DF359A13F7Q33803804-94956A39-644E-47C9-AAD0-B9747299F33EQ34279715-55FEFA7B-B016-44A0-8D5B-A44C90170B29Q34832611-BA27DB03-6AA6-4BAC-A0E3-A78289317162Q35387846-4FA07804-014C-4D60-A384-CA1E8CCE0AA5Q35561746-73004EC5-4480-4303-A94F-F83346CCFF8AQ35728637-BE6521FD-5238-4FC3-BD0E-4150FC83A45BQ35846963-E1E95428-2BB9-4AD6-9FEF-492BD209F85EQ35917162-B16C8A83-7F11-47EE-B803-293216F697C0Q36078279-8B18C86B-784E-43F3-A639-3D5D65CD6222Q36269199-0FB56EA5-A884-4E79-BB2A-62A7701A306BQ36908611-DB09DD97-5424-45A1-9A97-77C60F24A26BQ37079714-8D380D53-1DA1-43D2-A6DB-695382F715E8Q37137721-2BB4D3A3-71B1-4618-97CD-CD52A36BDD55Q37196045-DCECCAC1-2EC3-4A0D-9D43-2C13655C3A5FQ37201035-3EA96523-D28B-4242-B220-CA499233B259Q37233057-40EFFD3B-A9E3-4F24-AA34-9BDAA1C0735BQ37357543-17D653B8-4B38-40D7-B2EF-1ECBD830AB19Q37649782-61E1ECE1-72AF-4459-B9B0-13674FB7530BQ37678465-D7BAB7FF-18CB-41AF-BE21-2A51363581F1Q37928961-8EB8C7A3-70A7-4593-9E17-200D250C093CQ38102101-3E0C856D-52CA-4A5B-A76F-EC59A3702CD2Q38289442-5770EF0F-CE7B-4C97-8CDC-A7B951D7A131Q38309572-BFF94988-268A-42CC-92ED-6B23EBCFEB45Q38766552-3AA4712D-0763-4D36-930C-D361A513A9F5Q38772827-CEAC0E5A-24D2-4E37-9016-81A686751978Q39289010-31F39F88-CBF6-4DA8-9A47-DABE22BC9A77Q39835313-3335111D-C4DF-41E9-9E38-7E0803EFFB9FQ40209304-98737FCC-1EE7-4B0A-9F07-69F92F331514Q41070585-6CA66554-414B-4970-9C84-9421CA696ECFQ42573665-8F189799-1C67-4CFB-B202-A95B60992D18Q43878336-451BA6AC-A5AB-43EB-9E60-8A353C1443A4Q45791692-AC9D9B90-BCF9-4093-A955-868213D48E82Q45872036-E6D2E326-01C2-42A1-A04A-747A93559CC6
P2860
Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term clinical outcome of ...... t-transplant GVHD prophylaxis.
@en
Long-term clinical outcome of ...... t-transplant GVHD prophylaxis.
@nl
type
label
Long-term clinical outcome of ...... t-transplant GVHD prophylaxis.
@en
Long-term clinical outcome of ...... t-transplant GVHD prophylaxis.
@nl
prefLabel
Long-term clinical outcome of ...... t-transplant GVHD prophylaxis.
@en
Long-term clinical outcome of ...... t-transplant GVHD prophylaxis.
@nl
P2860
P921
P1476
Long-term clinical outcome of ...... t-transplant GVHD prophylaxis.
@en
P2093
Mary Dell Railey
Rebecca H Buckley
P2860
P304
834-840.e1
P356
10.1016/J.JPEDS.2009.07.049
P407
P577
2009-10-09T00:00:00Z